Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.
Horwitz SM, Nirmal AJ, Rahman J, Xu R, Drill E, Galasso N, Ganesan N, Davey T, Hancock H, Perez L, Maccaro C, Bahgat A, Marzouk E, Cathcart E, Moskowitz A, Noy A, Kumar A, Jacobsen E, Fisher DC, Mehta-Shah N, Kim YH, Khodadoust M, Kotlov N, Nikitina A, Kudryashova O, Zubareva V, Zornikova K, Shin N, Sorokina M, Degryse S, Postovalova E, Bagaev A, Hosszu K, McAvoy D, Boelens JJ, Wu W, Ciantra Z, Appelt JW, Trevisani C, Amaka S, Weinstock DM, Vardhana SA.
Horwitz SM, et al. Among authors: weinstock dm.
Nat Med. 2024 Jun 17. doi: 10.1038/s41591-024-03076-6. Online ahead of print.
Nat Med. 2024.
PMID: 38886623